title: Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.
abstract: Poorly differentiated thyroid cancer lesions often lose the ability to concentrate radioactive [131I]iodine (RAI) and exhibit increased metabolic activity, as evidenced by enhanced glucose uptake. We incorporated [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) scanning into the routine follow-up of a cohort of thyroid cancer patients undergoing annual evaluations. One hundred and twenty-five patients who had previous thyroidectomies were included. They had diagnostic RAI whole body scans, serum thyroglobulin measurements, and additional imaging studies as clinically indicated. During 41 months of follow-up, 14 patients died. Univariate analysis demonstrated that survival was reduced in those with age over 45 yr, distant metastases, PET positivity, high rates of FDG uptake, and high volume of the FDG-avid disease (>125 mL). Survival did not correlate with gender, RAI uptake, initial histology, or grade. Multivariate analysis demonstrated that the single strongest predictor of survival was the volume of FDG-avid disease. The 3-yr survival probability of patients with FDG volumes of 125 mL or less was 0.96 (95% confidence interval, 0.91, 1.0) compared with 0.18 (95% confidence interval, 0.04, 0.85) in patients with FDG volume greater than 125 mL. Only 1 death (of leukemia) occurred in the PET-negative group (n = 66). Of the 10 patients with distant metastases and negative PET scans, all were alive and well. Patients over 45 yr with distant metastases that concentrate FDG are at the highest risk. Once distant metastases are discovered in patients with differentiated thyroid carcinoma, FDG-PET can identify high and low risk subsets. Subjects with a FDG volume greater than 125 mL have significantly reduced short term survival.
authors.affiliation: Department of Radiology, The Laurent and Alberta Gerschel PET Center, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA.
authors.forename: W
authors.initials: W
authors.lastname: Wang
authors.forename: S M
authors.initials: SM
authors.lastname: Larson
authors.forename: M
authors.initials: M
authors.lastname: Fazzari
authors.forename: S K
authors.initials: SK
authors.lastname: Tickoo
authors.forename: K
authors.initials: K
authors.lastname: Kolbert
authors.forename: G
authors.initials: G
authors.lastname: Sgouros
authors.forename: H
authors.initials: H
authors.lastname: Yeung
authors.forename: H
authors.initials: H
authors.lastname: Macapinlac
authors.forename: J
authors.initials: J
authors.lastname: Rosai
authors.forename: R J
authors.initials: RJ
authors.lastname: Robbins
mesh_terms: D000328:Adult; D000367:Age Factors; D000704:Analysis of Variance; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012737:Sex Factors; D016019:Survival Analysis; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D014055:Tomography, Emission-Computed
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18